Scientists in the US say they have developed an mRNA-based vaccine that encompasses all 20 known subtypes of influenza that could form the basis of a future universal jab.
In its first set of quarterly results since it separated from its consumer health business, GSK has exceeded analysts' estimates, with a healthy rise in revenue and profit driven by shingle
Australia's CSL is the latest vaccines company to buy into the mRNA category, tapping US biotech Arcturus Therapeutics for a wide-ranging alliance targeting COVID-19, influenza and other re
The UK company reveals the results from a partner-led survey to discover the rates of vaccination for adults, why levels are lower than expected, and what can be done to improve this.
Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl